title: Guidelines for the treatment and management of new-onset diabetes after transplantation.
abstract: Although graft and patient survival after solid organ transplantation have improved markedly in recent years, transplant recipients continue to experience an increased prevalence of cardiovascular disease (CVD) compared with the general population. A number of factors are known to impact on the increased risk of CVD in this population, including hypertension, dyslipidemia and diabetes mellitus. Of these factors, new-onset diabetes after transplantation has been identified as one of the most important, being associated with reduced graft function and patient survival, and increased risk of graft loss. In 2003, International Consensus Guidelines on New-onset Diabetes after Transplantation were published, which aimed to establish a precise definition and diagnosis of the condition and recommend management strategies to reduce its occurrence and impact. These updated 2004 guidelines, developed in consultation with the International Diabetes Federation (IDF), extend the recommendations of the previous guidelines and encompass new-onset diabetes after kidney, liver and heart transplantation. It is hoped that adoption of these management approaches pre- and post-transplant will reduce individuals' risk of developing new-onset diabetes after transplantation as well as ameliorating the long-term impact of this serious complication.
authors.affiliation: David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
authors.forename: Alan
authors.initials: A
authors.lastname: Wilkinson
authors.forename: Jaime
authors.initials: J
authors.lastname: Davidson
authors.forename: Francesco
authors.initials: F
authors.lastname: Dotta
authors.forename: Philip D
authors.initials: PD
authors.lastname: Home
authors.forename: Paul
authors.initials: P
authors.lastname: Keown
authors.forename: Bryce
authors.initials: B
authors.lastname: Kiberd
authors.forename: Alan
authors.initials: A
authors.lastname: Jardine
authors.forename: Naomi
authors.initials: N
authors.lastname: Levitt
authors.forename: Piero
authors.initials: P
authors.lastname: Marchetti
authors.forename: Mariana
authors.initials: M
authors.lastname: Markell
authors.forename: Sarala
authors.initials: S
authors.lastname: Naicker
authors.forename: Philip
authors.initials: P
authors.lastname: O'Connell
authors.forename: Mark
authors.initials: M
authors.lastname: Schnitzler
authors.forename: Eberhard
authors.initials: E
authors.lastname: Standl
authors.forename: Jose-Vicente
authors.initials: JV
authors.lastname: Torregosa
authors.forename: Kazuharu
authors.initials: K
authors.lastname: Uchida
authors.forename: Hannah
authors.initials: H
authors.lastname: Valantine
authors.forename: Federico
authors.initials: F
authors.lastname: Villamil
authors.forename: Flavio
authors.initials: F
authors.lastname: Vincenti
authors.forename: Martin
authors.initials: M
authors.lastname: Wissing
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000628:therapy; D003920:Diabetes Mellitus / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016377:Organ Transplantation / Q000009:adverse effects*; D017410:Practice Guidelines as Topic
chemical_list: D007166:Immunosuppressive Agents